- Home
- VALN vs MREO Comparison
VALN vs MREO Comparison
Compare VALN & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALN
- MREO
- Stock Information
- Founded
- VALN 2012
- MREO 2015
- Country
- VALN France
- MREO United Kingdom
- Employees
- VALN N/A
- MREO N/A
- Industry
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- VALN Health Care
- MREO Health Care
- Exchange
- VALN Nasdaq
- MREO Nasdaq
- Market Cap
- VALN 510.7M
- MREO 424.5M
- IPO Year
- VALN 2021
- MREO N/A
- Fundamental
- Price
- VALN $6.28
- MREO $2.19
- Analyst Decision
- VALN Strong Buy
- MREO Strong Buy
- Analyst Count
- VALN 3
- MREO 7
- Target Price
- VALN $15.33
- MREO $7.71
- AVG Volume (30 Days)
- VALN 83.3K
- MREO 943.2K
- Earning Date
- VALN 05-07-2025
- MREO 05-13-2025
- Dividend Yield
- VALN N/A
- MREO N/A
- EPS Growth
- VALN N/A
- MREO N/A
- EPS
- VALN N/A
- MREO N/A
- Revenue
- VALN $201,099,222.00
- MREO N/A
- Revenue This Year
- VALN $18.74
- MREO N/A
- Revenue Next Year
- VALN $29.26
- MREO $54.91
- P/E Ratio
- VALN N/A
- MREO N/A
- Revenue Growth
- VALN 21.64
- MREO N/A
- 52 Week Low
- VALN $3.62
- MREO $1.58
- 52 Week High
- VALN $9.50
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- VALN 47.26
- MREO 43.17
- Support Level
- VALN $6.18
- MREO $2.11
- Resistance Level
- VALN $6.54
- MREO $2.27
- Average True Range (ATR)
- VALN 0.18
- MREO 0.13
- MACD
- VALN 0.02
- MREO -0.02
- Stochastic Oscillator
- VALN 45.65
- MREO 16.41
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).